Acadia’s Launch Of Daybue Astonishes Analysts
Secures Global Rights For Rett Syndrome Drug
Not content with a stunning launch in the US, Acadia has splashed out $100m to bag the worldwide rights from partner Neuren for Rett syndrome therapy Daybue.
Not content with a stunning launch in the US, Acadia has splashed out $100m to bag the worldwide rights from partner Neuren for Rett syndrome therapy Daybue.